105 related articles for article (PubMed ID: 27271482)
1. Efficacy and safety of erythrocytapheresis and low-dose erythropoietin for treatment of hemochromatosis.
Brückl D; Kamhieh-Milz S; Kamhieh-Milz J; Salama A
J Clin Apher; 2017 Jun; 32(3):170-174. PubMed ID: 27271482
[TBL] [Abstract][Full Text] [Related]
2. [Effectiveness of therapeutic erythrocytapheresis to achieve iron depletion in hereditary type 1 hemochromatosis: report of 30 cases].
Poullin P; Lefèvre PA
Transfus Clin Biol; 2011 Dec; 18(5-6):553-8. PubMed ID: 22019606
[TBL] [Abstract][Full Text] [Related]
3. Course of iron parameters in HFE-hemochromatosis patients during initial treatment with erythrocytapheresis compared to phlebotomy.
Rombout-Sestrienkova E; Koek GH; Neslo R; van Kraaij M; Menheere PP; Masclee A; Swinkels DW
J Clin Apher; 2016 Dec; 31(6):564-570. PubMed ID: 26878994
[TBL] [Abstract][Full Text] [Related]
4. Erythrocytapheresis with recombinant human erythropoietin in hereditary hemochromatosis therapy: a new alternative.
Kohan A; Niborski R; Daruich J; Rey J; Bastos F; Amerise G; Herrera R; García M; Olivera W; Santarelli MT; Avalos JS; Findor J
Vox Sang; 2000; 79(1):40-5. PubMed ID: 10971213
[TBL] [Abstract][Full Text] [Related]
5. Erythrocytapheresis plus erythropoietin: an alternative therapy for selected patients with hemochromatosis and severe organ damage.
Mariani R; Pelucchi S; Perseghin P; Corengia C; Piperno A
Haematologica; 2005 May; 90(5):717-8. PubMed ID: 15921401
[TBL] [Abstract][Full Text] [Related]
6. A predictive model for estimating the number of erythrocytapheresis or phlebotomy treatments for patients with naïve hereditary hemochromatosis.
Rombout-Sestrienkova E; Winkens B; van Kraaij M; van Deursen CTBM; Janssen MCH; Rennings AMJ; Evers D; Kerkhoffs JL; Masclee A; Koek GH
J Clin Apher; 2021 Jun; 36(3):340-347. PubMed ID: 33368569
[TBL] [Abstract][Full Text] [Related]
7. Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary haemochromatosis.
Sundic T; Hervig T; Hannisdal S; Assmus J; Ulvik RJ; Olaussen RW; Berentsen S
Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s84-9. PubMed ID: 24333062
[TBL] [Abstract][Full Text] [Related]
8. The efficiency of therapeutic erythrocytapheresis compared to phlebotomy: a mathematical tool for predicting response in hereditary hemochromatosis, polycythemia vera, and secondary erythrocytosis.
Evers D; Kerkhoffs JL; Van Egmond L; Schipperus MR; Wijermans PW
J Clin Apher; 2014 Jun; 29(3):133-8. PubMed ID: 24130064
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic erythrocytapheresis in the initial treatment of hereditary hemochromatosis.
Rehácek V; Bláha M; Jirousová H; Cernohorská J; Papousek P
Acta Medica (Hradec Kralove); 2012; 55(4):180-5. PubMed ID: 23631289
[TBL] [Abstract][Full Text] [Related]
10. Repeated isovolemic large-volume erythrocytapheresis in the treatment of idiopathic hemochromatosis.
Kellner H; Zoller WG
Z Gastroenterol; 1992 Nov; 30(11):779-83. PubMed ID: 1471384
[TBL] [Abstract][Full Text] [Related]
11. Erythrocytapheresis versus phlebotomy in the maintenance treatment of HFE hemochromatosis patients: results from a randomized crossover trial.
Rombout-Sestrienkova E; Winkens B; Essers BA; Nieman FH; Noord PA; Janssen MC; van Deursen CT; Boonen A; Reuser-Kaasenbrood EP; Heeremans J; van Kraaij M; Masclee A; Koek GH
Transfusion; 2016 Jan; 56(1):261-70. PubMed ID: 26358375
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic erythrocytapheresis versus phlebotomy in the initial treatment of hereditary hemochromatosis - A pilot study.
Rombout-Sestrienkova E; van Noord PA; van Deursen CT; Sybesma BJ; Nillesen-Meertens AE; Koek GH
Transfus Apher Sci; 2007 Jun; 36(3):261-7. PubMed ID: 17569592
[TBL] [Abstract][Full Text] [Related]
13. Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial.
Rombout-Sestrienkova E; Nieman FH; Essers BA; van Noord PA; Janssen MC; van Deursen CT; Bos LP; Rombout F; van den Braak R; de Leeuw PW; Koek GH
Transfusion; 2012 Mar; 52(3):470-7. PubMed ID: 21848963
[TBL] [Abstract][Full Text] [Related]
14. Oral vitamin C supplementation reduces erythropoietin requirement in hemodialysis patients with functional iron deficiency.
Sultana T; DeVita MV; Michelis MF
Int Urol Nephrol; 2016 Sep; 48(9):1519-24. PubMed ID: 27170339
[TBL] [Abstract][Full Text] [Related]
15. Recovery of pancreatic beta-cell function in hemochromatosis: combined treatment with recombinant human erythropoietin and phlebotomy.
Inoue Y; Nakanishi K; Hiraga T; Okubo M; Murase T; Kosaka K; Miyakoshi S; Mutoh Y; Kobayashi T
Am J Med Sci; 1997 Dec; 314(6):401-2. PubMed ID: 9413346
[TBL] [Abstract][Full Text] [Related]
16. In hereditary hemochromatosis, red cell apheresis removes excess iron twice as fast as manual whole blood phlebotomy.
Muncunill J; Vaquer P; Galmés A; Obrador A; Parera M; Bargay J; Besalduch J
J Clin Apher; 2002; 17(2):88-92. PubMed ID: 12210712
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of erythrocytapheresis in idiopathic hemochromatosis. Report of 14 cases.
Conte D; Mandelli C; Cesana M; Ferrini R; Marconi M; Bianchi A
Int J Artif Organs; 1989 Jan; 12(1):59-62. PubMed ID: 2925263
[TBL] [Abstract][Full Text] [Related]
18. How we manage patients with hereditary haemochromatosis.
Rombout-Sestrienkova E; van Kraaij MG; Koek GH
Br J Haematol; 2016 Dec; 175(5):759-770. PubMed ID: 27723100
[TBL] [Abstract][Full Text] [Related]
19. Effect of phlebotomy on lipid metabolism in subjects with hereditary hemochromatosis.
Casanova-Esteban P; Guiral N; Andrés E; Gonzalvo C; Mateo-Gallego R; Giraldo P; Paramo JA; Civeira F
Metabolism; 2011 Jun; 60(6):830-4. PubMed ID: 20846699
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and treatment of hereditary hemochromatosis: an update.
Kanwar P; Kowdley KV
Expert Rev Gastroenterol Hepatol; 2013 Aug; 7(6):517-30. PubMed ID: 23985001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
